{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:42:00Z","timestamp":1778582520052,"version":"3.51.4"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejim.2021.08.023","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T02:06:21Z","timestamp":1632362781000},"page":"6-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-2336","authenticated-orcid":false,"given":"Cas J.","family":"Isfordink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raoel","family":"Maan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"de Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4034-5444","authenticated-orcid":false,"given":"Karel J.","family":"van Erpecum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriaan J.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2021.08.023_bib0001","unstructured":"World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240027077externalicon."},{"key":"10.1016\/j.ejim.2021.08.023_bib0002","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ejim.2021.08.023_bib0003","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"European association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0004","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"De Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0006","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","author":"van der Meer","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0007","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0149-2918(11)00022-1","article-title":"A review of the treatment of chronic hepatitis C virus infection in cirrhosis","volume":"32","author":"Vezali","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2021.08.023_bib0008","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0009","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.023_bib0010","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus","volume":"8","author":"Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0011","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1053\/j.gastro.2015.07.056","article-title":"Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US Veterans, 2001-2013","volume":"149","author":"Beste","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0012","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of hcv prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0013","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2021.08.023_bib0014","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/bjs5.50226","article-title":"Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv","volume":"4","author":"Henriksson","year":"2020","journal-title":"BJS Open"},{"key":"10.1016\/j.ejim.2021.08.023_bib0015","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0016","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2005.03.019","article-title":"Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial","volume":"43","author":"Di Bisceglie","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0017","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/apt.12370","article-title":"Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography - a randomised study","volume":"38","author":"Pocha","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2021.08.023_bib0018","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaoncol.2016.3147","article-title":"MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma","volume":"3","author":"Kim","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejim.2021.08.023_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001624","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis","volume":"11","author":"Singal","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejim.2021.08.023_bib0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0021","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.amjmed.2017.01.021","article-title":"Hepatocellular carcinoma screening associated with early tumor detection and improved survival among patients with cirrhosis in the US","volume":"130","author":"Singal","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2021.08.023_bib0022","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.04.027","article-title":"Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study","volume":"155","author":"Costentin","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0023","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","article-title":"Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival","volume":"53","author":"Santi","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0024","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.24545","article-title":"Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities","volume":"54","author":"Trinchet","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0025","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jhep.2015.06.012","article-title":"Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands","volume":"63","author":"Van Meer","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0026","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1053\/j.gastro.2018.06.079","article-title":"No association between screening for hepatocellular carcinoma and reduced cancer-related mortality in patients with cirrhosis","volume":"155","author":"Moon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.30129","article-title":"Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial","volume":"69","author":"Singal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0028","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/hep.30330","article-title":"Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis","volume":"69","author":"Kim","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0029","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.cgh.2013.11.033","article-title":"Post-treatment levels of \u03b1-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy","volume":"12","author":"Oze","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0030","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","author":"Farhang Zangneh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0031","series-title":"SEER cancer statistics review, 1975-2015","author":"Noone","year":"2018"},{"key":"10.1016\/j.ejim.2021.08.023_bib0032","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","article-title":"Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma","volume":"157","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0033","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0034","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2021.08.023_bib0035","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2021.08.023_bib0036","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0037","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2017.10.033","article-title":"The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen","volume":"68","author":"Innes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0038","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0039","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0040","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jhep.2019.01.005","article-title":"Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules","volume":"70","author":"Mari\u00f1o","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0041","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/hep.30303","article-title":"Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with chronic hepatitis C in the United States","volume":"69","author":"Park","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0042","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection","volume":"17","author":"Degasperi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0043","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2021.08.023_bib0044","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/liv.14041","article-title":"Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma","volume":"39","author":"Pi\u00f1ero","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2021.08.023_bib0045","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jvh.13276","article-title":"Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: a prospective study","volume":"27","author":"Shiha","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ejim.2021.08.023_bib0046","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0047","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","article-title":"Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals","volume":"72","author":"Pons","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0048","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/hep.31500","article-title":"Hepatic fat\u2014genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated with DAAs","volume":"72","author":"Degasperi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0049","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s12072-020-10105-2","article-title":"HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort","volume":"14","author":"Tanaka","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ejim.2021.08.023_bib0050","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0051","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.31588","article-title":"A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus\u2013advanced fibrosis","volume":"72","author":"Alonso L\u00f3pez","year":"2020","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ejim.2021.08.023_bib0052","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.3390\/cancers12092602","article-title":"Incidence of hepatocellular carcinoma after treatment with sofosbuvir-based or sofosbuvir-free regimens in patients with chronic hepatitis C","volume":"12","author":"Ogawa","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejim.2021.08.023_bib0053","first-page":"2205","article-title":"Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct\u2013acting antiviral treatment: all Kagawa liver disease group study","volume":"19","author":"Tani","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ejim.2021.08.023_bib0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0243473","article-title":"Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis","volume":"15","author":"Abe","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2021.08.023_bib0055","first-page":"ciaa1307","article-title":"Change in fibrosis 4 index as predictor of high risk of incident hepatocellular carcinoma after eradication of hepatitis C virus","author":"Tamaki","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejim.2021.08.023_bib0056","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/apt.14427","article-title":"Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis","volume":"47","author":"Mettke","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2021.08.023_bib0057","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study","volume":"69","author":"Romano","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0058","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","article-title":"Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C","volume":"69","author":"Ioannou","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0059","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0060","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/liv.13629","article-title":"Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon\/ribavirin-free treatment","volume":"38","author":"Kozbial","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2021.08.023_bib0061","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0062","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0063","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1055\/s-0037-1608775","article-title":"Overdiagnosis: an understudied issue in hepatocellular carcinoma surveillance","volume":"37","author":"Rich","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejim.2021.08.023_bib0064","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u20132021 update","volume":"0","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2013.03.013","article-title":"The diagnostic accuracy of Fibroscan\u00ae for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response","volume":"59","author":"D'Ambrosio","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0066","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/apt.13722","article-title":"The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study","volume":"44","author":"Sultanik","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2021.08.023_bib0067","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jhep.2020.06.032","article-title":"Towards personalized screening for hepatocellular carcinoma: still not there","volume":"73","author":"Calvaruso","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0068","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0069","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0070","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2021.08.023_bib0071","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0168-8278(02)00420-8","article-title":"Incidence and natural history of small esophageal varices in cirrhotic patients","volume":"38","author":"Merli","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0072","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0073","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hep.1840050313","article-title":"Portal pressure, presence of gastroesophageal varices and variceal bleeding","volume":"5","author":"Garcia-Tsao","year":"1985","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0074","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.cgh.2009.08.011","article-title":"Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis","volume":"7","author":"Augustin","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jhep.2007.10.008","article-title":"Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy","volume":"48","author":"Abraldes","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0076","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-2007-1007133","article-title":"Pharmacological treatment of portal hypertension: an evidence-based approach","volume":"19","author":"D'Amico","year":"1999","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10.1016\/j.ejim.2021.08.023_bib0077","article-title":"Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices","volume":"6","author":"Vadera","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.ejim.2021.08.023_bib0078","article-title":"Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults","author":"Gluud","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2021.08.023_bib0079","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cgh.2019.04.062","article-title":"Performance of Baveno VI and Expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"17","author":"Stafylidou","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0080","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.cgh.2007.02.022","article-title":"Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis","volume":"5","author":"Roberts","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0081","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","article-title":"Sustained virologic response prevents the development of esophageal varices in compensated, child-pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0082","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP1807","article-title":"The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon\/ribavirin therapy","volume":"16","author":"D'Ambrosio","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ejim.2021.08.023_bib0083","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/apt.13844","article-title":"Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV\/HCV patients with advanced liver disease","volume":"45","author":"Schwabl","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2021.08.023_bib0084","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jvh.12706","article-title":"Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension","volume":"24","author":"Afdhal","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ejim.2021.08.023_bib0085","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1093\/cid\/ciaa502","article-title":"Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis","volume":"71","author":"D\u00edez","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejim.2021.08.023_bib0086","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0087","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.30885","article-title":"Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy","volume":"71","author":"Mandorfer","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0088","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jgh.13252","article-title":"Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis","volume":"31","author":"van der Meer","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0089","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0090","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.3748\/wjg.v25.i21.2665","article-title":"Management of betablocked patients after sustained virological response in hepatitis C cirrhosis","volume":"25","author":"Abad\u00eda","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0091","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/jcm9010095","article-title":"Impact of sustained virological response for gastroesophageal varices in hepatitis-C-virus-related liver cirrhosis","volume":"9","author":"Yuri","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2021.08.023_bib0092","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","article-title":"Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy","volume":"156","author":"Thabut","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.08.023_bib0093","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00535-019-01619-0","article-title":"Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV\u2013cirrhotic patients","volume":"55","author":"Puigveh\u00ed","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0094","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jvh.13426","article-title":"Variceal recurrence 4 years post endoscopic band ligation in hepatitis C patients who achieved sustained virological response with oral direct-acting antiviral therapy","volume":"28","author":"Ibrahim","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ejim.2021.08.023_bib0095","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/hepr.13554","article-title":"Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients","volume":"50","author":"Nagaoki","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ejim.2021.08.023_bib0096","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/eci.13231","article-title":"Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C virus clearance in compensated advanced chronic liver disease","volume":"50","author":"Giannini","year":"2020","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejim.2021.08.023_bib0097","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0098","article-title":"Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis","author":"Wang","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.08.023_bib0099","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/apt.15586","article-title":"Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding","volume":"51","author":"Moon","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2021.08.023_bib0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jgh3.12091","article-title":"Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients","volume":"2","author":"Romano","year":"2018","journal-title":"JGH Open"},{"key":"10.1016\/j.ejim.2021.08.023_bib0101","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1140","article-title":"Liver stiffness\u2013based strategies predict absence of variceal bleeding in cirrhotic hepatitis C virus\u2013infected patients with and without human immunodeficiency virus coinfection after sustained virological response","author":"Corma-G\u00f3mez","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejim.2021.08.023_bib0102","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s10620-015-3865-8","article-title":"Facility- and patient-level factors associated with esophageal variceal screening in the USA","volume":"61","author":"Flemming","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.ejim.2021.08.023_bib0103","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/apt.15320","article-title":"Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage study","volume":"50","author":"McDonald","year":"2019","journal-title":"Aliment Pharmacol Ther"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362052100296X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362052100296X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:34:23Z","timestamp":1760607263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362052100296X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":103,"alternative-id":["S095362052100296X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.08.023","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}